Neutropenia
Welcome,         Profile    Billing    Logout  
 413 Companies   276 Products   276 Products   144 Mechanisms of Action   556 Trials   44796 News 


«12...345678910111213...626627»
  • ||||||||||  paclitaxel / Generic mfg., Tasigna (nilotinib) / Novartis, Inhibikase
    P1 data, Journal:  A phase 1 study of nilotinib in combination with paclitaxel in patients with advanced solid tumors. (Pubmed Central) -  Mar 19, 2025   
    This study determined the MTD of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism of action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.
  • ||||||||||  Synribo (omacetaxine mepesuccinate) / Teva, Zalypsis (PM00104) / PharmaMar
    Review, Journal:  Translating molecular insights into clinical success: alkaloid-based therapies for leukemia. (Pubmed Central) -  Mar 18, 2025   
    This review discusses several potent alkaloids, such as homoharringtonine, chaetominine, matrine, and jerantinine B, which induce apoptosis, cell cycle arrest, and autophagy and inhibit signaling pathways including PI3K/Akt/mTOR, MAPK, and NF-?B...In addition, targeting leukemia stem cells (LSCs) with alkaloids such as zalypsis offers promise due to its ability to induce apoptosis without significantly affecting normal hematopoietic stem cells...For example, jerantinine B targets AML cells, while vincristine has shown success in lymphocytic leukemia...However, adverse effects such as neutropenia and hepatotoxicity necessitate careful management. Collectively, these findings emphasize the need for further research into alkaloid-based combination therapies to enhance efficacy and minimize toxicity, providing a promising avenue for innovative leukemia treatments.
  • ||||||||||  Journal:  An Atypical Presentation of Sweet's Syndrome in a Patient With Neutropenia: A Case Report. (Pubmed Central) -  Mar 18, 2025   
    We report an atypical presentation of Sweet Syndrome in a 54-year-old female with neutropenia and myelodysplastic syndrome to enhance awareness and management of this rare condition among hospitalists. It demonstrates how SS can develop in the context of chemotherapy-induced neutropenia, thereby highlighting the importance of recognizing this case presentation in relevant clinical scenarios.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Ceftazidime-avibactam use in hematology patients: single-center experience. (Pubmed Central) -  Mar 18, 2025   
    Age, pneumonia and need for mechanical ventilation and duration of neutropenia are the most important mortality indicators in hematologic patients. Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops.
  • ||||||||||  Trial completion date:  NEXUS: Next-Generation-Sequencing Approach to Neutropenic Sepsis (clinicaltrials.gov) -  Mar 17, 2025   
    P=N/A,  N=400, Recruiting, 
    Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops. Trial completion date: Jul 2025 --> Jan 2026
  • ||||||||||  Review, Journal:  Cytopenias in Autoimmune Liver Diseases-A Review. (Pubmed Central) -  Mar 17, 2025   
    This review aims to act as a guide for the clinician dealing with patients with AiLDs with respect to the occurrence of cytopenias, with a specific focus on pathophysiology and management of these cytopenias. Furthermore, there need to be enhanced multidisciplinary discussions about those patients between the hematologists and hepatologists, with a maintenance of a high index of suspicion for the rarer causes of cytopenias in AiLDs on the part of the treating physician, and there is a need for further studies to elucidate the mechanisms behind the occurrence of cytopenias in AiLDs.
  • ||||||||||  Journal, Mismatch repair, MSi-H Biomarker, IO biomarker:  Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis. (Pubmed Central) -  Mar 17, 2025   
    We have uncovered a biological basis for ICAHT and provide support for the use of IFN?-blockade to reduce CRS and neutropenia. Compared to the ICIs and TKIs combination therapy, the radiotherapy, ICIs, and TKIs triple therapy can further improve the disease control rate and serum tumor marker levels in MSS or pMMR CCLM patients without increasing the risk of related adverse reactions, making it a treatment regimen worthy of further validation.
  • ||||||||||  Journal:  Cyclic neutropenia: a case report and literature review. (Pubmed Central) -  Mar 17, 2025   
    For patients with periodic changes in clinical manifestations accompanied by granulocyte deficiency, bone marrow puncture and genetic testing of genes related to granulocyte deficiency should be performed. In patients with neutropenia, genetic testing can aid in the diagnosis of CyN.
  • ||||||||||  Journal:  Oncostatin M silence and neopeptide: the value of exploring patients with rare inherited bone marrow failure. (Pubmed Central) -  Mar 17, 2025   
    In this issue of the JCI, Garrigue, Kermasson, and colleagues identified a homozygous variant in Oncostatin M (OSM) in 3 children from a consanguineous family presenting with IBMFS characterized by profound anemia, thrombocytopenia, and neutropenia. The findings suggest that the loss-of-function OSM variant affected hematopoietic stem cell function through changes to the bone marrow microenvironment (BMM).
  • ||||||||||  Journal:  Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment (2025 edition) (Pubmed Central) -  Mar 17, 2025   
    Due to the delay in its clinical manifestation, a well-established out-of-hospital management system can help clinicians better prevent and manage the myelosuppression associated with oncology treatment and ensure the effectiveness and safety of antitumor therapy. This consensus focuses on a detailed compilation and summary of the definition and grading of myelosuppression associated with oncological treatment, the principles of out-of-hospital management, the management process and management methods, develops a risk stratification assessment table for oncology treatment-related myelosuppression, and puts forward 8 recommendations based on the risk stratification, which is aimed at providing medical workers with a reference plan for the out-of-hospital management of myelosuppression associated with oncological treatment.
  • ||||||||||  Journal:  Characterization of the Phenotypic Consequences of the Duffy-Null Genotype. (Pubmed Central) -  Mar 17, 2025   
    Further, we find that race is not an accurate predictor of Duffy-null status or associated benign neutropenia. Our research suggests that broad genetic screening of rs2814778 across all populations could provide a more robust and accurate understanding of white blood cell count and mitigate resulting health disparities.
  • ||||||||||  Review, Journal:  Neutropenia and SARS-CoV-2 infection, A review of the literature. (Pubmed Central) -  Mar 16, 2025   
    In this study, our aim was to conduct a comprehensive review of the current literature on neutropenia during or after SARS-CoV2 infection. Furthermore, we assessed whether there have been any documented cases of immune-mediated neutropenia following COVID-19 and if the appropriate laboratory investigations have been carried out in these patients.
  • ||||||||||  YL201 / MediLink
    P1 data, Journal:  A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. (Pubmed Central) -  Mar 14, 2025   
    P1, P1/2
    YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker...Phase 3 clinical trials for patients with SCLC and NPC have already been initiated. ClinicalTrials.gov identifiers: NCT05434234 and NCT06057922 .
  • ||||||||||  gemcitabine / Generic mfg.
    Journal, Adverse events, Real-world evidence, Real-world:  A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for gemcitabine. (Pubmed Central) -  Mar 14, 2025   
    Gemcitabine is associated with a broad spectrum of AEs affecting multiple organ systems, with a notable incidence of hospitalization. The study highlights both expected and unexpected AEs, which could enhance future clinical applications and safety of gemcitabine.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Filgrastim induced glomerulonephritis (GN) () -  Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_712;    
    He was given the presumptive diagnose of filgrastim-induced GN and treated with Cytoxan and iv pulse steroids...He was admitted a week later for Melphalan and autologous stem cell transplant...The exact mechanism is unknown, but it is possible that G-CSF causes a large transient increase in neutrophils that may have triggered an autoimmune inflammatory process in the kidneys to the monoclonal IG deposition that was known to be deposited there.Conclusion Filgrastim is a rare cause of hematuria and GN. We treated it by holding the filgrastim and treating it with immunosuppressive agents.